Session » Vasculitis – ANCA-Associated Poster II

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2720

30-Day Hospital Readmission for Granulomatosis with Polyangiitis: Analysis from National Readmission Database

9:00AM-11:00AM: Abstract Number: 2738

A Randomized Phase 3 Trial Evaluating the Safety and Efficacy of Avacopan in Patients with New or Relapsing Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2741

Candidate Biomarkers in ANCA-Associated Vasculitis Identified Using a Proteomic Approach

9:00AM-11:00AM: Abstract Number: 2740

Clinical and Laboratory Characteristics of ANCA-Associated Vasculitis in Pediatric and Young Adult Patients: A Retrospective Review

9:00AM-11:00AM: Abstract Number: 2725

Clinical Characteristics and Long-Term Follow-up of 382 Microscopic Polyangiitis Patients

9:00AM-11:00AM: Abstract Number: 2731

Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital

9:00AM-11:00AM: Abstract Number: 2718

Comparison of Various ANCA Detection Methods in Predominantly MPO ANCA-Associated Vasculitis Cohort

9:00AM-11:00AM: Abstract Number: 2717

Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized–Controlled Trials

9:00AM-11:00AM: Abstract Number: 2743

Favorable Efficacy of Rituximab in ANCA-Associated Vasculitis Patients with Excessive B Cell Differentiation

9:00AM-11:00AM: Abstract Number: 2733

From a Myth to a Menace: Increased Disease Severity and Poor Outcomes in an Urban Cohort of African-American Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2730

Handgrip Strength Predicts the Risk of Bone Fracture and Severe Adverse Events in Patients with Systemic Necrotizing Vasculitis

9:00AM-11:00AM: Abstract Number: 2735

Identifying ANCA-Associated Vasculitis Cases in Electronic Health Records Using Natural Language Processing

9:00AM-11:00AM: Abstract Number: 2722

Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results

9:00AM-11:00AM: Abstract Number: 2729

Increased Risk of Cerebrovascular Accident Among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-Analysis of Cohort Studies

9:00AM-11:00AM: Abstract Number: 2737

Opportunistic Infections in Medium and Small-Sized Vessel Vasculitis: Based on a Retrospectivestudy on 108 Patients

9:00AM-11:00AM: Abstract Number: 2723

Patient Experience in ANCA-Associated Vasculitis Evolves over Time from Diagnosis and Both Benefits and Adverse Impacts Are Felt with Current Therapy

9:00AM-11:00AM: Abstract Number: 2732

Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center

9:00AM-11:00AM: Abstract Number: 2727

Prevalence of Clinical and Subclinical Ophthalmologic Manifestations in Association with Systemic Symptoms, Disease Activity and Damage in Patients with Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 2742

Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study

9:00AM-11:00AM: Abstract Number: 2726

Severe Infections in Systemic Necrotizing Vasculitis: Incidence and Risk Factors

9:00AM-11:00AM: Abstract Number: 2739

Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events

9:00AM-11:00AM: Abstract Number: 2734

The Effect of Age at Diagnosis on Mortality in ANCA-Associated Vasculitides

9:00AM-11:00AM: Abstract Number: 2719

Tracking the Risk of Infections in ANCA-Associated Vasculitis: Results from a Scottish Matched-Cohort Study

9:00AM-11:00AM: Abstract Number: 2728

Validation of the Draft Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Indian Patients with ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2736

Value of Histology for Diagnosis and Classification in ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2724

Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU

9:00AM-11:00AM: Abstract Number: 2721

Venous Thromboembolism in ANCA Associated Vasculitis. a Population-Based Cohort Study from Southern Sweden

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].